OncoSec Medical Incorporated (NASDAQ:ONCS) Receives $5.67 Average Target Price from Analysts

Shares of OncoSec Medical Incorporated (NASDAQ:ONCS) have earned an average recommendation of “Buy” from the six analysts that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $5.33.

ONCS has been the topic of a number of recent research reports. Maxim Group reaffirmed a “buy” rating and set a $5.00 price objective on shares of OncoSec Medical in a report on Friday, May 12th. HC Wainwright set a $6.00 price objective on OncoSec Medical and gave the company a “buy” rating in a report on Monday, May 22nd. ValuEngine downgraded OncoSec Medical from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Noble Financial reissued a “buy” rating on shares of OncoSec Medical in a report on Friday, May 12th. Finally, Dawson James reissued a “buy” rating and issued a $5.00 target price on shares of OncoSec Medical in a report on Thursday, July 6th.

COPYRIGHT VIOLATION NOTICE: “OncoSec Medical Incorporated (NASDAQ:ONCS) Receives $5.67 Average Target Price from Analysts” was reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The correct version of this story can be read at https://www.chaffeybreeze.com/2017/07/30/oncosec-medical-incorporated-nasdaqoncs-receives-5-67-consensus-price-target-from-analysts-updated-updated-updated.html.

Shares of OncoSec Medical (NASDAQ ONCS) opened at 0.9901 on Tuesday. The company’s 50 day moving average price is $1.10 and its 200-day moving average price is $1.20. OncoSec Medical has a 12 month low of $0.88 and a 12 month high of $2.08. The firm’s market capitalization is $20.96 million.

OncoSec Medical (NASDAQ:ONCS) last released its quarterly earnings data on Thursday, June 1st. The biotechnology company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.06. On average, equities analysts predict that OncoSec Medical will post ($1.02) earnings per share for the current fiscal year.

About OncoSec Medical

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.

Analyst Recommendations for OncoSec Medical (NASDAQ:ONCS)

Receive News & Ratings for OncoSec Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply